R&D Trends

BIND Therapeutics, Roche collaborate on discovery of novel nanomedicines

Friday, June 20, 2014 12:07 PM

BIND Therapeutics, a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, has entered into a research agreement with Roche to discover novel nanomedicines using Accurins for the treatment of diseases in therapeutic areas outside of oncology. The collaboration will focus on combining BIND's Accurin technology with Roche's proprietary therapeutic payloads and targeting ligands.

More... »

WIRB Copernicus Group

Report: More than 430 medicines in development for chronic diseases in elderly

Thursday, June 19, 2014 01:44 PM

America’s biopharmaceutical research companies are developing 435 innovative new medicines to target 15 leading chronic conditions affecting the Medicare population, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

More... »


Medical Research Council launches U.K. Dementias Research Platform

Thursday, June 19, 2014 01:39 PM

The Medical Research Council (MRC) has launched the U.K. Dementias Research Platform (UKDP), a $27.2 million public-private partnership set up to speed up research into dementias. The collaboration aims to enable earlier detection, improved treatment and, ultimately, prevention of the disease by looking not just at what is going wrong in the brain, but at the brain in the context of the whole body.

More... »

ADDC, AstraZeneca partner for drug development in academic research

Wednesday, June 18, 2014 12:54 PM

The Academic Drug Discovery Consortium (ADDC) has formed a collaboration with AstraZenecaaimed at facilitating efforts by researchers from academia and institutions toward the discovery of novel compounds with potential pharmaceutical application. More specifically, the goal of this partnership is to provide ADDC members with access to a high-quality compound library, while allowing AZ the opportunity to collaborate with academic researchers to identify novel disease targets and drugs across a wide range of therapy areas.

More... »

Sanofi, Medtronic form diabetes alliance to improve patient experience, outcomes

Wednesday, June 18, 2014 12:50 PM

Sanofi, a global healthcare provider, and Medtronic, a global medical technology provider, have entered into a global strategic alliance in diabetes, aimed at improving patient experience and outcomes for people with diabetes around the world. The alliance will initially focus on two key priorities: the development of drug-device combinations and delivery of care management services to improve adherence, simplify insulin treatment and help people with diabetes better manage their condition.

More... »

Selecta Biosciences, 3SBio ink agreement for gout

Wednesday, June 18, 2014 12:49 PM

Selecta Biosciences, a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune tolerance treatments, has entered into an exclusive license with 3SBio, a biotechnology company researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, for pegsiticase (Uricase PEG-20), a pegylated recombinant uricase from candida utilis.

More... »

Pfizer, Cellectis enter global cancer immunotherapy collaboration

Wednesday, June 18, 2014 12:47 PM

Pfizer and Cellectis, a biopharmaceutical company focused on oncology, have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies directed at select targets.

More... »

TrovaGene, Dana-Farber Cancer Institute collaborate

Tuesday, June 17, 2014 11:12 AM

Trovagene has entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time in metastatic melanoma patients.

More... »

TransCelerate BioPharma launches two new global initiatives

Monday, June 16, 2014 11:47 AM

TransCelerate BioPharma is launching two new global initiatives enabled by broad participation and collaboration across the R&D community: to develop a position on the best and most efficient methods for redacting privacy information found in clinical study reports and an approach for the anonymization of patient-level data shared with the broader healthcare community; and to develop a framework for a Quality Management System (QMS) specifically for clinical research to improve the quality and efficiency of clinical trials.

More... »

KalGene Pharmaceuticals forms multi-year collaboration for aggressive cancers

Friday, June 13, 2014 01:14 PM

KalGene Pharmaceuticals, a developer of a prognostic marker and companion therapeutic that specifically targets aggressive cancers, has formed a multi-stage and multi-year collaboration with the Center for Imaging Technology Commercialization (CIMTEC), Sunnybrook Research Institute (SRI) and the Ontario Cancer Biomarker Network (OCBN) at Queen's University.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

August 18

Ebola outbreak highlights need to improve biosafety, infrastructure to handle future health emergencies

More African American professional women open to participating in medical research

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs